ArticleInternational urology and nephrology2026
Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the "PI-RADS 3 + 1" subgroup.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePI-RADS (Prostate Imaging Reporting and Data System) category 3 lesions harbor a heterogeneous risk of clinically significant prostate cancer (csPCa). They are less frequently biopsied in contemporary practice. Peripheral zone lesions upgraded from PI-RADS 3 to 4 solely based on dynamic contrast enhancement (DCE) ("PI-RADS 3 + 1") may represent a distinct subgroup. We aimed to assess the prevalence of csPCa in this subset.
methodsWe conducted a single-center study based on a prospectively maintained database, including consecutive patients with a single PI-RADS 3 + 1 lesion identified at our institution who underwent prostate biopsy between November 2023 and November 2025. csPCa was defined as International Society of Urological Pathology (ISUP) grade group ≥ 2.
resultsAmong 55 patients, prostate cancer was detected in 35 cases (64%), including 16 csPCa (29%). Most biopsies (71%) did not yield csPCa. High-grade disease (ISUP GG ≥ 3) was identified in only two patients (4%). csPCa detection rates were higher in patients with PSAd ≥ 0.15 (39% vs 19%). A PSAd-based strategy would have avoided 49% of biopsies but missed 31% of csPCa cases. PSAd showed modest discrimination (AUC 0.65). Lesion size was not associated with csPCa and demonstrated poor discrimination (AUC 0.41).
conclusionsPI-RADS 3 + 1 lesions appear to represent an intermediate-risk subgroup between conventional PI-RADS 3 and PI-RADS 4 lesions. csPCa was detected in nearly one-third of patients, supporting individualized biopsy decision-making rather than automatic management as conventional PI-RADS 4 lesions.
Indexed as
Identifiers
42435107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.